- Oral presentation
- Open Access
Vascular and renal function of cGMP signalling
BMC Pharmacology volume 11, Article number: O17 (2011)
Signalling by NO/cGMP is significant for regulation of cardiovascular and renal function.
For the functional analysis of cGMP signalling, transgenic murine mutants were used. cGKI signalling pathways include interaction of the cGKIβ-isozyme with the inositol 1,4,5-trisphosphate receptor I (IP3RI) associated protein cGMP kinase substrate (IRAG). NO/cGMP and ANP/cGMP-dependent relaxation of aortic smooth muscle was strongly affected in IRAG-deficient mice. NO/ANP-dependent inhibition of intracellular calcium release was suppressed in IRAG-deficient vascular smooth muscle cells (VSMC). Furthermore, reduction of store operated calcium entry by cGMP was affected in IRAG-KO VSMC. Basal mean arterial blood pressure, heart rate and activity were not changed in IRAG knockout mice. However, under pathophysiological conditions like sepsis (induced by E. coli lipopolysaccharide application) IRAG knockout mice were resistant to blood pressure reduction.
These results suggested that cGKI/IRAG signalling is a predominant signal transduction pathway of NO/ANP/cGMP which may be involved in vascular diseases including pathophysiological modulation of blood pressure. Further results provided evidence that cGMP signalling is essential for prevention of renal diseases suppressing interstitial fibrosis.
About this article
Cite this article
Schlossmann, J., Schinner, E., Desch, M. et al. Vascular and renal function of cGMP signalling. BMC Pharmacol 11 (Suppl 1), O17 (2011). https://doi.org/10.1186/1471-2210-11-S1-O17
- Blood Pressure
- Renal Function
- Vascular Disease
- Signal Transduction Pathway